PD-1/PD-L1 targeted therapies achieved good results in immunologically “hot” tumors (non-small cell lung, renal, or bladder cancers, melanoma, etc.), while immunologically “cold” neoplasms can be resistant [639,640,641,642,643,644,645,646,647,648,649,650,651,652,653,654,655,656,657,658,659,660,661,662,663,664,665]. Here, CD274 is linked to neoplasm.